Treatment trends and Medicare reimbursements for localized prostate cancer in elderly patients

P Dell’Oglio, AS Valiquette, SR Leyh-Bannurah, Z Tian, V Trudeau, A Larcher, SF Shariat, U Capitanio, A Briganti, M Graefen, F Montorsi, PI Karakiewicz

Research output: Contribution to journalArticle

Abstract

Introduction: The absolute and proportional numbers of elderly patients diagnosed with localized prostate cancer (PCa) are on the rise. We examined treatment trends and reimbursement figures in localized PCa patients aged ≥80 years. Methods: Between 2000 and 2008, we identified 30 217 localized PCa patients aged ≥80 years in Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked database. Alternative treatment modalities consisted of conservative management (CM), radiation therapy (RT), radical prostatectomy (RP), and primary androgen-deprivation therapy (PADT). For all four modalities, utilization and reimbursements were examined. Results: PADT was the most frequently used treatment modality between 2000 and 2005. CM became the dominant treatment modality from 2006‒2008. RP rates were marginal. RT ranked third, and its annual rate increased from 20.77% in 2000 to 29.13% in 2008. Median individual reimbursement of RT was highest and ranged from $29 343 in 2000 to $31 090 in 2008, followed by RP (from $20 560 in 2000 to $19 580 in 2008), PADT (from $18 901 in 2000 to $8000 in 2008), and CM (from $1824 in 2000 to $1938 in 2008). RT contributed to most of the cumulative annual reimbursements from 2003 (49.24%) to 2008 (72.97%). PADT ranked first from 2000 (54.56%) to 2002 (50.49%), but decreased by 19.40% in 2008. CM’s contribution increased from 4.42% in 2000 to 6.96% in 2008. RP’s share of reimbursements was stable during the study period. Conclusions: Our results, focusing on localized PCa treatment in patients aged ≥80 years, showed an important increase in rates, median cost, and proportion of cumulative cost related to RT. © 2018 Canadian Urological Association.
Original languageEnglish
Pages (from-to)E338-E344
JournalJournal of the Canadian Urological Association
Volume12
Issue number7
DOIs
Publication statusPublished - 2018

Fingerprint

Medicare
Prostatic Neoplasms
Radiotherapy
Androgens
Prostatectomy
Therapeutics
Costs and Cost Analysis
Epidemiology
Databases

Cite this

Dell’Oglio, P., Valiquette, AS., Leyh-Bannurah, SR., Tian, Z., Trudeau, V., Larcher, A., ... Karakiewicz, PI. (2018). Treatment trends and Medicare reimbursements for localized prostate cancer in elderly patients. Journal of the Canadian Urological Association, 12(7), E338-E344. https://doi.org/10.5489/cuaj.4865

Treatment trends and Medicare reimbursements for localized prostate cancer in elderly patients. / Dell’Oglio, P; Valiquette, AS; Leyh-Bannurah, SR; Tian, Z; Trudeau, V; Larcher, A; Shariat, SF; Capitanio, U; Briganti, A; Graefen, M; Montorsi, F; Karakiewicz, PI.

In: Journal of the Canadian Urological Association, Vol. 12, No. 7, 2018, p. E338-E344.

Research output: Contribution to journalArticle

Dell’Oglio, P, Valiquette, AS, Leyh-Bannurah, SR, Tian, Z, Trudeau, V, Larcher, A, Shariat, SF, Capitanio, U, Briganti, A, Graefen, M, Montorsi, F & Karakiewicz, PI 2018, 'Treatment trends and Medicare reimbursements for localized prostate cancer in elderly patients', Journal of the Canadian Urological Association, vol. 12, no. 7, pp. E338-E344. https://doi.org/10.5489/cuaj.4865
Dell’Oglio, P ; Valiquette, AS ; Leyh-Bannurah, SR ; Tian, Z ; Trudeau, V ; Larcher, A ; Shariat, SF ; Capitanio, U ; Briganti, A ; Graefen, M ; Montorsi, F ; Karakiewicz, PI. / Treatment trends and Medicare reimbursements for localized prostate cancer in elderly patients. In: Journal of the Canadian Urological Association. 2018 ; Vol. 12, No. 7. pp. E338-E344.
@article{1553a987e0d141819b19b3517cb6dbc0,
title = "Treatment trends and Medicare reimbursements for localized prostate cancer in elderly patients",
abstract = "Introduction: The absolute and proportional numbers of elderly patients diagnosed with localized prostate cancer (PCa) are on the rise. We examined treatment trends and reimbursement figures in localized PCa patients aged ≥80 years. Methods: Between 2000 and 2008, we identified 30 217 localized PCa patients aged ≥80 years in Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked database. Alternative treatment modalities consisted of conservative management (CM), radiation therapy (RT), radical prostatectomy (RP), and primary androgen-deprivation therapy (PADT). For all four modalities, utilization and reimbursements were examined. Results: PADT was the most frequently used treatment modality between 2000 and 2005. CM became the dominant treatment modality from 2006‒2008. RP rates were marginal. RT ranked third, and its annual rate increased from 20.77{\%} in 2000 to 29.13{\%} in 2008. Median individual reimbursement of RT was highest and ranged from $29 343 in 2000 to $31 090 in 2008, followed by RP (from $20 560 in 2000 to $19 580 in 2008), PADT (from $18 901 in 2000 to $8000 in 2008), and CM (from $1824 in 2000 to $1938 in 2008). RT contributed to most of the cumulative annual reimbursements from 2003 (49.24{\%}) to 2008 (72.97{\%}). PADT ranked first from 2000 (54.56{\%}) to 2002 (50.49{\%}), but decreased by 19.40{\%} in 2008. CM’s contribution increased from 4.42{\%} in 2000 to 6.96{\%} in 2008. RP’s share of reimbursements was stable during the study period. Conclusions: Our results, focusing on localized PCa treatment in patients aged ≥80 years, showed an important increase in rates, median cost, and proportion of cumulative cost related to RT. {\circledC} 2018 Canadian Urological Association.",
author = "P Dell’Oglio and AS Valiquette and SR Leyh-Bannurah and Z Tian and V Trudeau and A Larcher and SF Shariat and U Capitanio and A Briganti and M Graefen and F Montorsi and PI Karakiewicz",
year = "2018",
doi = "10.5489/cuaj.4865",
language = "English",
volume = "12",
pages = "E338--E344",
journal = "Journal of the Canadian Urological Association",
issn = "1911-6470",
publisher = "Canadian Medical Association",
number = "7",

}

TY - JOUR

T1 - Treatment trends and Medicare reimbursements for localized prostate cancer in elderly patients

AU - Dell’Oglio, P

AU - Valiquette, AS

AU - Leyh-Bannurah, SR

AU - Tian, Z

AU - Trudeau, V

AU - Larcher, A

AU - Shariat, SF

AU - Capitanio, U

AU - Briganti, A

AU - Graefen, M

AU - Montorsi, F

AU - Karakiewicz, PI

PY - 2018

Y1 - 2018

N2 - Introduction: The absolute and proportional numbers of elderly patients diagnosed with localized prostate cancer (PCa) are on the rise. We examined treatment trends and reimbursement figures in localized PCa patients aged ≥80 years. Methods: Between 2000 and 2008, we identified 30 217 localized PCa patients aged ≥80 years in Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked database. Alternative treatment modalities consisted of conservative management (CM), radiation therapy (RT), radical prostatectomy (RP), and primary androgen-deprivation therapy (PADT). For all four modalities, utilization and reimbursements were examined. Results: PADT was the most frequently used treatment modality between 2000 and 2005. CM became the dominant treatment modality from 2006‒2008. RP rates were marginal. RT ranked third, and its annual rate increased from 20.77% in 2000 to 29.13% in 2008. Median individual reimbursement of RT was highest and ranged from $29 343 in 2000 to $31 090 in 2008, followed by RP (from $20 560 in 2000 to $19 580 in 2008), PADT (from $18 901 in 2000 to $8000 in 2008), and CM (from $1824 in 2000 to $1938 in 2008). RT contributed to most of the cumulative annual reimbursements from 2003 (49.24%) to 2008 (72.97%). PADT ranked first from 2000 (54.56%) to 2002 (50.49%), but decreased by 19.40% in 2008. CM’s contribution increased from 4.42% in 2000 to 6.96% in 2008. RP’s share of reimbursements was stable during the study period. Conclusions: Our results, focusing on localized PCa treatment in patients aged ≥80 years, showed an important increase in rates, median cost, and proportion of cumulative cost related to RT. © 2018 Canadian Urological Association.

AB - Introduction: The absolute and proportional numbers of elderly patients diagnosed with localized prostate cancer (PCa) are on the rise. We examined treatment trends and reimbursement figures in localized PCa patients aged ≥80 years. Methods: Between 2000 and 2008, we identified 30 217 localized PCa patients aged ≥80 years in Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked database. Alternative treatment modalities consisted of conservative management (CM), radiation therapy (RT), radical prostatectomy (RP), and primary androgen-deprivation therapy (PADT). For all four modalities, utilization and reimbursements were examined. Results: PADT was the most frequently used treatment modality between 2000 and 2005. CM became the dominant treatment modality from 2006‒2008. RP rates were marginal. RT ranked third, and its annual rate increased from 20.77% in 2000 to 29.13% in 2008. Median individual reimbursement of RT was highest and ranged from $29 343 in 2000 to $31 090 in 2008, followed by RP (from $20 560 in 2000 to $19 580 in 2008), PADT (from $18 901 in 2000 to $8000 in 2008), and CM (from $1824 in 2000 to $1938 in 2008). RT contributed to most of the cumulative annual reimbursements from 2003 (49.24%) to 2008 (72.97%). PADT ranked first from 2000 (54.56%) to 2002 (50.49%), but decreased by 19.40% in 2008. CM’s contribution increased from 4.42% in 2000 to 6.96% in 2008. RP’s share of reimbursements was stable during the study period. Conclusions: Our results, focusing on localized PCa treatment in patients aged ≥80 years, showed an important increase in rates, median cost, and proportion of cumulative cost related to RT. © 2018 Canadian Urological Association.

U2 - 10.5489/cuaj.4865

DO - 10.5489/cuaj.4865

M3 - Article

VL - 12

SP - E338-E344

JO - Journal of the Canadian Urological Association

JF - Journal of the Canadian Urological Association

SN - 1911-6470

IS - 7

ER -